FB918 is a fully-human antibody drug to target interleukin 33 (IL-33). It was developed by Oneness Biotech by screening a human antibody library, and is now in the pre-clinical development stage. Currently, all the major pharmaceutical companies are enthusiastic in exploring new indications of IL-33 drugs, making IL-33 a promising new drug target.
Today, the treatment of non-allergic eosinophilic asthma is still an unmet medical need. Patients of this disease show an increase in group II innate lymphoid cells (ILC2), which when stimulated by the IL-33 secreted by epithelial cells cause maturation and migration of eosinophils and thus lead to an attack of the disease. Statistics show that the global market of asthma treatment in 2019 was about USD 18 billion, and the market size is predicted to reach USD 26 billion in 2027.
|Research Code||Therapeutic Area||Indication||Pre-Clinical||Phase I||Phase II||Phase III||NDA||Market||More|
FB918 is a first-in-class antibody targeting the interleukin 33 (IL-33) for asthma. It has been discovered and developed from Oneness-owned antibody library